We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 368

Will You, Won't You Join The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • February 21 2017

In the latest dispute surrounding the “patent dance” provisions of the Biologics Price Competition and Innovation Act (BPCIA), Genentech, Inc. has


PTAB Puts Method Of Treatment Patents Under The 101 Knife
  • Foley & Lardner LLP
  • USA
  • February 28 2017

While the Supreme Court decisions in Myriad and Mayo have been applied to diagnostic-type claims, method of treatment patents were thought to be safe


Will The Avastin Biosimilar Patent Dance Go On?
  • Foley & Lardner LLP
  • USA
  • March 7 2017

Judge Sleet of the U.S. District Court for the District of Delaware has dismissed Genentech’s complaint against Amgen for allegedly failing to comply


PTAB Holds Oral Hearings In Tecfidera Patent IPR and Interference
  • Foley & Lardner LLP
  • USA
  • December 6 2016

On November 30, 2016, the USPTO Patent Trial and Appeal Board (PTAB) held oral hearings in two different inter partes proceedings involving the


Judge Lourie suggests Jepson claims for patent eligibility
  • Foley & Lardner LLP
  • USA
  • December 8 2015

As reported previously, the Federal Circuit has denied rehearing in Ariosa Diagnostics, Inc. v. Sequenom, Inc. I wrote about Judge 'Dyk's opinion


The PRICED Act Would Expedite Biosimilar Market Entry
  • Foley & Lardner LLP
  • USA
  • July 12 2016

Although the 12-year exclusivity period for original biologic products was a heavily negotiated provision of the Biologics Price Competition and


Court cites objects of invention in claim construction
  • Foley & Lardner LLP
  • USA
  • February 24 2015

Pacing Technologies, LLC v. Garmin International, Inc. is one of those Federal Circuit decisions that may send patent practitioners running to their


Patent Term Adjustment Versus Double Patenting
  • Foley & Lardner LLP
  • USA
  • February 25 2016

In Magna Electronics, Inc. v. TRW Automotive Holdings Corp., No. 1:12-cv-654; 1:13-cv-324 (Dec. 10, 2015), Judge Maloney of the U.S. District Court


Court Rejects Theory Of Derivation Based On FDA Requirement
  • Foley & Lardner LLP
  • USA
  • February 7 2017

The Federal Circuit decision in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC may be more interesting for what Mylan argued than for


Dispelling the Myriad gene patent harmonization myth
  • Foley & Lardner LLP
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the